VanEck Associates
ICPT

VanEck Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

VanEck Associates’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,274
Closed -$3.67M – 740
2017
Q2 		$3.67M Buy
30,274
+4,724
+18% +$547K 0.02% 319
2017
Q1 		$2.89M Buy
25,550
+2,161
+9% +$252K 0.01% 364
2016
Q4 		$2.54M Sell
23,389
-1,392
-6% -$166K 0.01% 373
2016
Q3 		$4.08M Sell
24,781
-6,165
-20% -$972K 0.02% 318
2016
Q2 		$4.42M Sell
30,946
-7,423
-19% -$1.08M 0.02% 286
2016
Q1 		$4.93M Sell
38,369
-7,359
-16% -$869K 0.03% 220
2015
Q4 		$6.83M Buy
45,728
+5,170
+13% +$875K 0.05% 207
2015
Q3 		$6.73M Sell
40,558
-13,201
-25% -$2.9M 0.05% 208
2015
Q2 		$13M Buy
53,759
+23,193
+76% +$6.18M 0.08% 189
2015
Q1 		$8.62M Buy
30,566
+1,816
+6% +$393K 0.05% 215
2014
Q4 		$4.49M Sell
28,750
-8,238
-22% -$1.52M 0.03% 272
2014
Q3 		$8.76M Sell
36,988
-419
-1% -$107K 0.05% 202
2014
Q2 		$8.85M Buy
37,407
+8,252
+28% +$2.17M 0.04% 208
2014
Q1 		$9.62M Buy
+29,155
New +$9.84M 0.05% 189

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VanEck Associates's ICPT Position: Q3 2017 in Review

VanEck Associates sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 30,274 shares — an estimated $3.67M sold.

VanEck Associates first reported a position in ICPT in Q1 2014 and held it in 14 quarters. The position peaked at $13M in Q2 2015. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

  • VanEck Associates reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • VanEck Associates sold 30,274 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $3.67M.
  • VanEck Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 14 quarters.
  • VanEck Associates's Intercept Pharmaceuticals, Inc. position peaked at $13M in Q2 2015.
  • 155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on VanEck Associates's 13F filing for Q3 2017, filed 9 Nov 2017.